Simultaneous Analysis of COVID-19 Drug Candidates in Human Plasma by LC-MS/MS

In 2019, the COVID19 caught the world almost by surprise. Its relentless spread over the world forced authorities to act rapidly to find an adequate treatment.

Besides drastic measure taken to lockdown half world population, some drugs targeting single strand RNA viruses, Malaria or even bacterial strains were propelled to the FDA fast track of testing and approval to fight this new threat. Lacking deep phase I-II studies, clinical centers and hospitals had to set their own protocol to administer the treatment. Since many bioanalytical labs were equipped with LCMS/MS, corresponding stable isotope labeled standards availability became critical to monitor the drugs.